Clinical Management of Long-Term Survivors after Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma

The Management of Patients with Limited-Stage Classical Hodgkin Lymphoma

Mary K. Gospodarowicz
Ralph M. Meyer

August 2015

The term limited-stage Hodgkin lymphoma refers to those patients with stage I-II disease and an abse...

Late Neurological and Cognitive Sequelae and Long-Term Monitoring of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi

Silvia Franceschetti
Maria Antonietta Annunziata
Giulia Agostinelli
Chiara Gerardi
Eleonora Allocati
Carla Minoia
Attilio Guarini

July 2021

Background: The continuously improving treatment outcome for classical Hodgkin lymphoma (cHL) and di...

Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma

Ekberg, Sara
Jerkeman, Mats
Andersson, Per Ola
Enblad, Gunilla
Wahlin, Björn E.
Hasselblom, Sverker
Andersson, Therese M.
Eloranta, Sandra
Smedby, Karin E.

August 2018

Survival has improved among patients with diffuse large B-cell lymphoma (DLBCL) with the addition of...

Long-Term Follow-Up of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: Aims and Methodological Approach for Fondazione Italiana Linfomi Systematic Reviews

Chiara Gerardi
Eleonora Allocati
Carla Minoia
Attilio Guarini
Rita Banzi

June 2021

Advances in diagnosis and treatment of hematological malignancies has boosted attention on optimal f...

Late sequelae and survivorship following treatment of Hodgkin's lymphoma

Behringer, K.
Halbsguth, T. V.
Borchmann, P.

January 2014

As a consequence of the impressive long-term remission rates in Hodgkin's lymphoma (HL) patients, cu...

Late cardiological sequelae and long-term monitoring in classical hodgkin lymphoma and diffuse large B-cell lymphoma survivors. A systematic review by the fondazione italiana linfomi

Oliva S.
Puzzovivo A.
Gerardi C.
Allocati E.
De Sanctis V.
Minoia C.
Skrypets T.
Guarini A.
Gini G.

January 2022

Cardiotoxicity represents the most frequent cause with higher morbidity and mortality among long-ter...

Treatment Responses, Toxicity, and Survival in Patients with Classical Hodgkin Lymphoma Aged >= 50 Years: A Single-Center Experience Over Two Decades

AR, MUHLİS CEM
ÖNGÖREN, ŞENİZ
BAŞLAR, ZAFER
EŞKAZAN, AHMET EMRE
Cokgezer, Simay
ELVERDİ, TUĞRUL
SALİHOĞLU, AYŞE

July 2022

Introduction: The aim of this study was to evaluate treatment responses, toxicity, and survival amon...

Late Cardiological Sequelae and Long-Term Monitoring in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi

Stefano Oliva
Agata Puzzovivo
Chiara Gerardi
Eleonora Allocati
Vitaliana De Sanctis
Carla Minoia
Tetiana Skrypets
Attilio Guarini
Guido Gini

December 2021

Cardiotoxicity represents the most frequent cause with higher morbidity and mortality among long-ter...

Disease- and treatment-related late sequelae in Hodgkin lymphoma

Behringer, K.
Oertel, M.
Rueffer, J. U.
Borchmann, P.

January 2022

Background Given the impressive long-term remission rates in recent years, current clinical research...

Long-term Hodgkin Lymphoma Survivors: A Glimpse of What Happens 10 Years After Treatment

Laddaga F. E.
Moschetta M.
Perrone T.
Perrini S.
Colonna P.
Ingravallo G.
D'abbicco D.
Specchia G.
Gaudio F.

January 2020

This study was focused on 96 patients with Hodgkin lymphoma: After ten years, 88% patients are alive...

The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future

S. E. Richardson
C. McNamara

January 2011

The management of classical Hodgkin's lymphoma (CHL) is a success story of modern multi-agent haemat...

Patient trajectories after diagnosis of diffuse large B-cell lymphoma—a multistate modelling approach to estimate the chance of lasting remission

Ekberg, Sara
Crowther, Michael
Harrysson, Sara
Jerkeman, Mats
E. Smedby, Karin
Eloranta, Sandra

January 2022

Background: Achieving lasting remission for at least 2 years is a good indicator for favourable prog...

Relapse risk and loss of lifetime after modern combined modality treatment of young patients with Hodgkin lymphoma: A Nordic lymphoma epidemiology group study

Biccler, Jorne Lionel
Glimelius, Ingrid
Eloranta, Sandra
Smeland, Knut Bjøro
Brown, Peter de Nully
Jakobsen, Lasse Hjort
Frederiksen, Henrik
Jerkeman, Mats
Fosså, Alexander
Andersson, Therese M.-L.
Holte, Harald
Bøgsted, Martin
El-Galaly, Tarec Christoffer
Smedby, Karin Ekström

January 2019

Estimates of short- and long-term survival for young patients with classic Hodgkin lymphoma (cHL) ar...

Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study

Maerevoet, Marie
Zijlstra, Josee M.
Follows, George
Casasnovas, Rene-Olivier
Vermaat, J. S. P.
Kalakonda, Nagesh
Goy, Andre
Choquet, Sylvain
Van den Neste, Eric
Hill, Brian
Thieblemont, Catherine
Cavallo, Federica
De la Cruz, Fatima
Kuruvilla, John
Hamad, Nada
Jaeger, Ulrich
Caimi, Paolo
Gurion, Ronit
Warzocha, Krzysztof
Bakhshi, Sameer
Sancho, Juan-Manuel
Schuster, Michael
Egyed, Miklos
Offner, Fritz
Vassilakopoulos, Theodoros P.
Samal, Priyanka
Ku, Matthew
Ma, Xiwen
Corona, Kelly
Chamoun, Kamal
Shah, Jatin
Shacham, Sharon
Kauffman, Michael G.
Canales, Miguel

January 2021

Patients with RR DLBCL who have received >= 2 lines of therapy have limited treatment options and an...

Long-term survival after treatment for Hodgkin’s disease (1973–2002): improved survival with successive 10-year cohorts

Em Bessell
G Bouliotis
S Armstrong
J Baddeley
Ap Haynes
H Nicholls-elliott
M Bradley

August 2016

BACKGROUND: The Nottinghamshire Lymphoma Registry contains the details of all the patients diagnosed...

The Management of Patients with Limited-Stage Classical Hodgkin Lymphoma

Mary K. Gospodarowicz
Ralph M. Meyer

August 2015

The term limited-stage Hodgkin lymphoma refers to those patients with stage I-II disease and an abse...

Late Neurological and Cognitive Sequelae and Long-Term Monitoring of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi

Silvia Franceschetti
Maria Antonietta Annunziata
Giulia Agostinelli
Chiara Gerardi
Eleonora Allocati
Carla Minoia
Attilio Guarini

July 2021

Background: The continuously improving treatment outcome for classical Hodgkin lymphoma (cHL) and di...

Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma

Ekberg, Sara
Jerkeman, Mats
Andersson, Per Ola
Enblad, Gunilla
Wahlin, Björn E.
Hasselblom, Sverker
Andersson, Therese M.
Eloranta, Sandra
Smedby, Karin E.

August 2018

Survival has improved among patients with diffuse large B-cell lymphoma (DLBCL) with the addition of...

Long-Term Follow-Up of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: Aims and Methodological Approach for Fondazione Italiana Linfomi Systematic Reviews

Chiara Gerardi
Eleonora Allocati
Carla Minoia
Attilio Guarini
Rita Banzi

June 2021

Advances in diagnosis and treatment of hematological malignancies has boosted attention on optimal f...

Late sequelae and survivorship following treatment of Hodgkin's lymphoma

Behringer, K.
Halbsguth, T. V.
Borchmann, P.

January 2014

As a consequence of the impressive long-term remission rates in Hodgkin's lymphoma (HL) patients, cu...

Late cardiological sequelae and long-term monitoring in classical hodgkin lymphoma and diffuse large B-cell lymphoma survivors. A systematic review by the fondazione italiana linfomi

Oliva S.
Puzzovivo A.
Gerardi C.
Allocati E.
De Sanctis V.
Minoia C.
Skrypets T.
Guarini A.
Gini G.

January 2022

Cardiotoxicity represents the most frequent cause with higher morbidity and mortality among long-ter...

Treatment Responses, Toxicity, and Survival in Patients with Classical Hodgkin Lymphoma Aged >= 50 Years: A Single-Center Experience Over Two Decades

AR, MUHLİS CEM
ÖNGÖREN, ŞENİZ
BAŞLAR, ZAFER
EŞKAZAN, AHMET EMRE
Cokgezer, Simay
ELVERDİ, TUĞRUL
SALİHOĞLU, AYŞE

July 2022

Introduction: The aim of this study was to evaluate treatment responses, toxicity, and survival amon...

Late Cardiological Sequelae and Long-Term Monitoring in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi

Stefano Oliva
Agata Puzzovivo
Chiara Gerardi
Eleonora Allocati
Vitaliana De Sanctis
Carla Minoia
Tetiana Skrypets
Attilio Guarini
Guido Gini

December 2021

Cardiotoxicity represents the most frequent cause with higher morbidity and mortality among long-ter...

Disease- and treatment-related late sequelae in Hodgkin lymphoma

Behringer, K.
Oertel, M.
Rueffer, J. U.
Borchmann, P.

January 2022

Background Given the impressive long-term remission rates in recent years, current clinical research...

Long-term Hodgkin Lymphoma Survivors: A Glimpse of What Happens 10 Years After Treatment

Laddaga F. E.
Moschetta M.
Perrone T.
Perrini S.
Colonna P.
Ingravallo G.
D'abbicco D.
Specchia G.
Gaudio F.

January 2020

This study was focused on 96 patients with Hodgkin lymphoma: After ten years, 88% patients are alive...

The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future

S. E. Richardson
C. McNamara

January 2011

The management of classical Hodgkin's lymphoma (CHL) is a success story of modern multi-agent haemat...

Patient trajectories after diagnosis of diffuse large B-cell lymphoma—a multistate modelling approach to estimate the chance of lasting remission

Ekberg, Sara
Crowther, Michael
Harrysson, Sara
Jerkeman, Mats
E. Smedby, Karin
Eloranta, Sandra

January 2022

Background: Achieving lasting remission for at least 2 years is a good indicator for favourable prog...

Relapse risk and loss of lifetime after modern combined modality treatment of young patients with Hodgkin lymphoma: A Nordic lymphoma epidemiology group study

Biccler, Jorne Lionel
Glimelius, Ingrid
Eloranta, Sandra
Smeland, Knut Bjøro
Brown, Peter de Nully
Jakobsen, Lasse Hjort
Frederiksen, Henrik
Jerkeman, Mats
Fosså, Alexander
Andersson, Therese M.-L.
Holte, Harald
Bøgsted, Martin
El-Galaly, Tarec Christoffer
Smedby, Karin Ekström

January 2019

Estimates of short- and long-term survival for young patients with classic Hodgkin lymphoma (cHL) ar...

Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study

Maerevoet, Marie
Zijlstra, Josee M.
Follows, George
Casasnovas, Rene-Olivier
Vermaat, J. S. P.
Kalakonda, Nagesh
Goy, Andre
Choquet, Sylvain
Van den Neste, Eric
Hill, Brian
Thieblemont, Catherine
Cavallo, Federica
De la Cruz, Fatima
Kuruvilla, John
Hamad, Nada
Jaeger, Ulrich
Caimi, Paolo
Gurion, Ronit
Warzocha, Krzysztof
Bakhshi, Sameer
Sancho, Juan-Manuel
Schuster, Michael
Egyed, Miklos
Offner, Fritz
Vassilakopoulos, Theodoros P.
Samal, Priyanka
Ku, Matthew
Ma, Xiwen
Corona, Kelly
Chamoun, Kamal
Shah, Jatin
Shacham, Sharon
Kauffman, Michael G.
Canales, Miguel

January 2021

Patients with RR DLBCL who have received >= 2 lines of therapy have limited treatment options and an...

Long-term survival after treatment for Hodgkin’s disease (1973–2002): improved survival with successive 10-year cohorts

Em Bessell
G Bouliotis
S Armstrong
J Baddeley
Ap Haynes
H Nicholls-elliott
M Bradley

August 2016

BACKGROUND: The Nottinghamshire Lymphoma Registry contains the details of all the patients diagnosed...

The Management of Patients with Limited-Stage Classical Hodgkin Lymphoma

Mary K. Gospodarowicz
Ralph M. Meyer

August 2015

The term limited-stage Hodgkin lymphoma refers to those patients with stage I-II disease and an abse...

Late Neurological and Cognitive Sequelae and Long-Term Monitoring of Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma Survivors: A Systematic Review by the Fondazione Italiana Linfomi

Silvia Franceschetti
Maria Antonietta Annunziata
Giulia Agostinelli
Chiara Gerardi
Eleonora Allocati
Carla Minoia
Attilio Guarini

July 2021

Background: The continuously improving treatment outcome for classical Hodgkin lymphoma (cHL) and di...

Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma

Ekberg, Sara
Jerkeman, Mats
Andersson, Per Ola
Enblad, Gunilla
Wahlin, Björn E.
Hasselblom, Sverker
Andersson, Therese M.
Eloranta, Sandra
Smedby, Karin E.

August 2018

Survival has improved among patients with diffuse large B-cell lymphoma (DLBCL) with the addition of...

Clinical Management of Long-Term Survivors after Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma

Abstract

Extracted data

Clinical Management of Long-Term Survivors after Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma

Abstract

Extracted data

Related items

Related items